PSA et suivi après traitement du cancer de la prostate

Fegoun, A. Benchikh El; Villers, Arnauld; Moreau, Jean‐Luc; Richaud, Pierre; Rébillard, Xavier; Beuzeboc, Philippe

doi:10.1016/j.purol.2007.12.010

Cited by 14 publications

(3 citation statements)

References 63 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cancer cells commonly exhibit genomic instability with the telomeres often being shorter than those in normal cells [27,30,31]. Based on the dynamics of the 3D telomere architecture of their CTCs (changes in number of short telomeres over time) at +0, +2, +6, +12, +18 and +24 months, patients were classified into five groups.…”

Section: Resultsmentioning

confidence: 99%

“…We are comparing different PSA end points as early surrogates for tumor response, such as six-months PSA end levels after ADT, six-month PSA end levels after RT, and twelve-months PSA end levels after completed ADT (+36 months). The cutoff values were chosen on the basis of previous reports in which PSA end levels above or equal to 0.1 ng/mL after radiotherapy and long-course androgen deprivation therapy are associated with an increased risk of recurrence [6,25,26,27].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Long-Term Dynamics of Three Dimensional Telomere Profiles in Circulating Tumor Cells in High-Risk Prostate Cancer Patients Undergoing Androgen-Deprivation and Radiation Therapy

Wark

Quon

Ong

et al. 2019

Cancers

View full text Add to dashboard Cite

Patient-specific assessment, disease monitoring, and the development of an accurate early surrogate of the therapeutic efficacy of locally advanced prostate cancer still remain a clinical challenge. Contrary to prostate biopsies, circulating tumor cell (CTC) collection from blood is a less-invasive method and has potential as a real-time liquid biopsy and as a surrogate marker for treatment efficacy. In this study, we used size-based filtration to isolate CTCs from the blood of 100 prostate cancer patients with high-risk localized disease. CTCs from five time points: +0, +2, +6, +12 and +24 months were analyzed. Consenting treatment-naïve patients with cT3, Gleason 8-10, or prostate-specific antigen > 20 ng/mL and non-metastatic prostate cancer were included. For all time points, we performed 3D telomere-specific quantitative fluorescence in situ hybridization on a minimum of thirty isolated CTCs. The patients were divided into five groups based on the changes of number of telomeres vs telomere lengths over time and into three clusters based on all telomere parameters found on diagnosis. Group 2 was classified as non-respondent to treatment and the Cluster 3 presented more aggressive phenotype. Additionally, we compared our telomere results with the PSA levels for each patient at 6 months of ADT, at 6 months of completed RT, and at 36 months post-initial therapy. CTCs of patients with PSA levels above or equal to 0.1 ng/mL presented significant increases of nuclear volume, number of telomeres, and telomere aggregates. The 3D telomere analysis of CTCs identified disease heterogeneity among a clinically homogeneous group of patients, which suggests differences in therapeutic responses. Our finding suggests a new opportunity for better treatment monitoring of patients with localized high-risk prostate cancer.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Long-Term Dynamics of Three Dimensional Telomere Profiles in Circulating Tumor Cells in High-Risk Prostate Cancer Patients Undergoing Androgen-Deprivation and Radiation Therapy

Wark

Quon

Ong

et al. 2019

Cancers

View full text Add to dashboard Cite

show abstract

“…Generally, the Se of Ch-PET/CT is significantly higher in patients with a PSAvel higher than 2 ng/mL/year or a PSAdt lower than 6 months [54]. The proposed PSAvel cut-off of 2 ng/mL/year seems to be the more reliable value to distinguish patients with a positive Ch-PET/CT examination from those with a negative scan in a more accurate way, even if there are some authors who suggest that patients with a PSAvel higher than 1 ng/mL/year could benefit by a Ch-PET/CT scan [55].…”

Section: Hybrid Imaging: Pet/ctmentioning

confidence: 99%

Advanced Imaging for the Early Diagnosis of Local Recurrence Prostate Cancer after Radical Prostatectomy

Panebianco

Barchetti

Musio

et al. 2014

BioMed Research International

View full text Add to dashboard Cite

Currently the diagnosis of local recurrence of prostate cancer (PCa) after radical prostatectomy (RT) is based on the onset of biochemical failure which is defined by two consecutive values of prostate-specific antigen (PSA) higher than 0.2 ng/mL. The aim of this paper was to review the current roles of advanced imaging in the detection of locoregional recurrence. A nonsystematic literature search using the Medline and Cochrane Library databases was performed up to November 2013. Bibliographies of retrieved and review articles were also examined. Only those articles reporting complete data with clinical relevance for the present review were selected. This review article is divided into two major parts: the first one considers the role of PET/CT in the restaging of PCa after RP; the second part is intended to provide the impact of multiparametric-MRI (mp-MRI) in the depiction of locoregional recurrence. Published data indicate an emerging role for mp-MRI in the depiction of locoregional recurrence, while the performance of PET/CT still remains unclear. Moreover Mp-MRI, thanks to functional techniques, allows to distinguish between residual glandular healthy tissue, scar/fibrotic tissue, granulation tissue, and tumour recurrence and it may also be able to assess the aggressiveness of nodule recurrence.

show abstract

Biochemical Recurrence: A Valuable Endpoint?

Langsenlehner

2013

Radiotherapy in Prostate Cancer

View full text Add to dashboard Cite

PSA et suivi après traitement du cancer de la prostate

Cited by 14 publications

References 63 publications

Long-Term Dynamics of Three Dimensional Telomere Profiles in Circulating Tumor Cells in High-Risk Prostate Cancer Patients Undergoing Androgen-Deprivation and Radiation Therapy

Long-Term Dynamics of Three Dimensional Telomere Profiles in Circulating Tumor Cells in High-Risk Prostate Cancer Patients Undergoing Androgen-Deprivation and Radiation Therapy

Advanced Imaging for the Early Diagnosis of Local Recurrence Prostate Cancer after Radical Prostatectomy

Biochemical Recurrence: A Valuable Endpoint?

Contact Info

Product

Resources

About